GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shionogi & Co Ltd (OTCPK:SGIOY) » Definitions » EV-to-FCF

Shionogi (Shionogi) EV-to-FCF : 11.03 (As of May. 17, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Shionogi EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shionogi's Enterprise Value is $9,429 Mil. Shionogi's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $855 Mil. Therefore, Shionogi's EV-to-FCF for today is 11.03.

The historical rank and industry rank for Shionogi's EV-to-FCF or its related term are showing as below:

SGIOY' s EV-to-FCF Range Over the Past 10 Years
Min: 8.06   Med: 16.5   Max: 57.79
Current: 11.76

During the past 13 years, the highest EV-to-FCF of Shionogi was 57.79. The lowest was 8.06. And the median was 16.50.

SGIOY's EV-to-FCF is ranked better than
74.66% of 521 companies
in the Drug Manufacturers industry
Industry Median: 24.13 vs SGIOY: 11.76

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), Shionogi's stock price is $11.40. Shionogi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.958. Therefore, Shionogi's PE Ratio for today is 11.90.


Shionogi EV-to-FCF Historical Data

The historical data trend for Shionogi's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shionogi EV-to-FCF Chart

Shionogi Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.35 18.43 25.95 8.72 13.03

Shionogi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.72 8.51 9.83 14.32 13.03

Competitive Comparison of Shionogi's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Shionogi's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shionogi's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shionogi's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Shionogi's EV-to-FCF falls into.



Shionogi EV-to-FCF Calculation

Shionogi's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=9428.938/855.213
=11.03

Shionogi's current Enterprise Value is $9,429 Mil.
Shionogi's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $855 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shionogi  (OTCPK:SGIOY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Shionogi's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=11.40/0.958
=11.90

Shionogi's share price for today is $11.40.
Shionogi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.958.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Shionogi EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Shionogi's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Shionogi (Shionogi) Business Description

Traded in Other Exchanges
Address
1-8, Doshomachi 3-chome, Chuo-ku, Osaka, JPN, 541-0045
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Shionogi (Shionogi) Headlines

From GuruFocus

Shionogi & Co Ltd R&D Meeting Transcript

By GuruFocus Research 02-14-2024

Shionogi & Co Ltd R&D Meeting Transcript

By GuruFocus Research 02-14-2024